- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Enliven Therapeutics Inc (ELVN)
Track today's live Enliven Therapeutics (ELVN) share price, performance and key data on this page with our current NASDAQ:ELVN stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Enliven Therapeutics share price on the NASDAQ exchange. Use the dropdown to switch exchange for the ELVN share price, head to our technical summary section, which provides analysis on Enliven Therapeutics share price buy/sell indicators using real-time data (or discuss the Enliven Therapeutics (ELVN) stock price today with other investors in the Enliven Therapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:ELVN share price (ISIN: US29337E1029) to enhance your trading decisions with our free investment tools and resources.
What Is the Enliven Therapeutics Inc Share Price Today?
The Enliven Therapeutics share price today is 49.675.
What Is the Stock Symbol for Enliven Therapeutics Inc
The stock symbol (or 'ticker') for Enliven Therapeutics Inc is "ELVN."
What Stock Exchange Does Enliven Therapeutics Inc Trade On?
Enliven Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Enliven Therapeutics Inc a Good Stock to Buy?
Determining whether Enliven Therapeutics (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:ELVN share price (ISIN: US29337E1029) to enhance your trading decisions with our free investment tools and resources.
What Is the Enliven Therapeutics Inc Share Price Today?
The Enliven Therapeutics share price today is 49.675.
What Is the Stock Symbol for Enliven Therapeutics Inc
The stock symbol (or 'ticker') for Enliven Therapeutics Inc is "ELVN."
What Stock Exchange Does Enliven Therapeutics Inc Trade On?
Enliven Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Enliven Therapeutics Inc a Good Stock to Buy?
Determining whether Enliven Therapeutics (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
NASDAQ
Currency in USD
49.675
+1.905(+3.99%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
47.190
49.720
52 wk Range
14.785
49.940
ELVN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
47.19049.720
52 wk Range
14.78549.940
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ELVN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
60.111
Upside
+21.01%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
- Form 144 Enliven Therapeutics For: 22 June
- Investing.com
- Form 4 Enliven Therapeutics Inc For: 24 June
- Investing.com
- Form 4 Enliven Therapeutics Inc For: 22 June
- Investing.com
- Form 4 Enliven Therapeutics Inc For: 24 June
- Investing.com
- Form 13D/A Enliven Therapeutics For: 24 June
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 60.111
(+21.01% Upside)
Earnings
Latest Release
07/05/2026
EPS / Forecast
-0.38 / -0.44
Revenue / Forecast
-- / --
Compare ELVN to Peers and Sector
Metrics to compare | ELVN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipELVNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −29.9x | −0.8x | −0.4x | |
PEG Ratio | −2.02 | −0.11 | 0.00 | |
Price/Book | 6.5x | 2.2x | 2.6x | |
Price / LTM Sales | - | 1.8x | 3.0x | |
Upside (Analyst Target) | 25.6% | 98.1% | 55.7% | |
Fair Value Upside | Unlock | 22.2% | 8.1% | Unlock |
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Enliven Therapeutics (NASDAQ: ELVN) Share Price Today?
The Enliven Therapeutics stock price today is 49.675 USD.
What Stock Exchange Does Enliven Therapeutics (ELVN) Trade On?
Enliven Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Enliven Therapeutics?
The stock symbol (also called a 'ticker') for Enliven Therapeutics is "ELVN."
What Is the Current Enliven Therapeutics Market Capitalisation?
As of today, Enliven Therapeutics (NASDAQ: ELVN) market cap is 2.990B USD.
What Is Enliven Therapeutics's (ELVN) Earnings Per Share (TTM)?
The Enliven Therapeutics EPS is currently -1.650 (Trailing Twelve Months).
When Is the Next Enliven Therapeutics Earnings Date?
Enliven Therapeutics's next earnings report will be released on 19/08/2026.
Is ELVN a Buy or Sell From a Technical Analyst Perspective?
Based on today's Enliven Therapeutics moving averages and other technical indicators, the daily buy/sell signal for ELVN stock is Strong Buy.
How Many Times Has Enliven Therapeutics Stock Split?
Enliven Therapeutics has split 1 times. (See the ELVN stock split history page for full effective split date and price information.)
How Many Employees Does Enliven Therapeutics Have?
Enliven Therapeutics has 61 employees, based on their latest Companies House report.
What is the current trading status of Enliven Therapeutics (NASDAQ: ELVN)?
As of 25/06/2026, Enliven Therapeutics (ELVN) is trading at a share price of 49.675 USD, with a previous close of 47.770 USD. The stock has fluctuated within a day range of 47.190 USD to 49.720 USD, while its 52-week range spans from 14.785 USD to 49.940 USD.
What Is Enliven Therapeutics (ELVN) Price Target According to Analysts?
The average 12-month price target for Enliven Therapeutics is 60.111 USD, with a high estimate of 80 USD and a low estimate of 45 USD. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +21.01% Upside potential.
What Is the ELVN Premarket Price?
ELVN's last pre-market stock price is 47.000 USD. The pre-market share volume is 70.000, and the stock has decreased by -0.770, or -1.610%.
What Is the ELVN After Hours Price?
ELVN's last after hours stock price is 47.081 USD, the stock has decreased by -0.689, or -1.440%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.